Globant and PharmaMar announced a partnership to accelerate oncology drug discovery using artificial intelligence. The collaboration will deploy Globant Enterprise AI to build a multi‑agent system that delivers more than 90 % accuracy in complex data retrieval and can reduce time to insights up to 15‑fold, enabling PharmaMar scientists to identify high‑potential drug candidates for clinical development more quickly.
Globant’s recent financials show a 4.7 % year‑over‑year decline in Q4 2025 revenue and a gross profit margin of 34.9 % versus 35.7 % in the prior year, while PharmaMar reported a 27 % increase in 2025 revenue to €221.4 million. The partnership aligns with Globant’s focus on AI‑driven solutions in healthcare and with PharmaMar’s strategy to modernize its R&D pipeline.
"Drug discovery has always been a race against time, and in oncology, that time can mean everything," said Dr. Javier Jimenez, Chief Medical Officer at PharmaMar. "By integrating Globant's AI technologies, we can process data from thousands of documents in seconds, simulate scenarios, and focus our research efforts where they have the highest potential to make a difference for patients." Ariel Capone, CEO of Globant’s Healthcare and Life Sciences AI Studio, added, "PharmaMar's vision proves what's possible when human intelligence and AI systems work side by side. By leveraging agentic AI, we're building a new model for drug discovery; one that brings precision and scalability to a field that directly impacts millions of lives."
The AI platform will analyze large volumes of scientific, regulatory, and clinical data, integrating internal databases with external sources such as the FDA and EMA. Over 20 specialized digital agents will operate across preclinical, clinical, regulatory, commercial, and strategy areas, prioritizing the top treatment‑indication combinations from thousands of research documents in a fraction of the time previously required. The system is designed to review more than 4,500 documents and identify 10 viable treatment‑indication combinations out of over 8,000 possibilities.
The partnership positions Globant as a key AI enabler in life sciences and gives PharmaMar a faster route to identify high‑potential candidates, potentially accelerating clinical development timelines. It reflects the broader industry trend of AI adoption in drug discovery and underscores both companies’ commitment to leveraging advanced technology to bring new oncology therapies to patients more quickly.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.